This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Schellekens, H. How similar do 'biosimilars' need to be? Nature Biotechnol. 22, 1357–1359 (2004).
Sheridan, C. First generic biologics finally approved. Nature Rev. Drug Discov. 5, 445 (2006).
Dove, A. Betting on biogenerics. Nature Biotechnol. 19, 117–120 (2001).
EMEA. Biotech medicines: first biosimilar drug on EU market. European Commission. Press release, [online] (2006).
Sandoz, Inc. Sandoz gets precedent-setting US approval for Omnitrope® as first follow on version of a previously approved recombinant biotechnology drug. Press release, [online] (2006).
EMEA/CHMP. Guideline on Similar Biological Medicinal Products containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues, [online] (2005).
EMEA/CHMP. Guideline on Similar Biological Medicinal Products containing Biotechnology-Derived Proteins as Active Substance: Quality Issues http://www.emea.eu.int/pdfs/human/biosimilar/4934805en.pdf (2005).
Ben-Maimon, C. S. & Garnick, R. Biogenerics at the crossroads. Nature Biotechnol. 24, 268–268 (2006)
Griffiths, S. From the analyst's couch: Betting on biogenerics. Nature Rev. Drug Discov. 3, 197–198 (2004)
Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nature Rev. Drug Discov. 1, 457–462 (2002).
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
FURTHER INFORMATION
European Medicines Evaluation Agency: Guidelines onbiosimilar medicinal products
Rights and permissions
About this article
Cite this article
Belsey, M., Harris, L., Das, R. et al. Biosimilars: initial excitement gives way to reality. Nat Rev Drug Discov 5, 535–536 (2006). https://doi.org/10.1038/nrd2093
Issue Date:
DOI: https://doi.org/10.1038/nrd2093
This article is cited by
-
Establishing analytical comparability for “biosimilars”: filgrastim as a case study
Analytical and Bioanalytical Chemistry (2014)
-
Patent term extensions for biologic innovators in Japan
Nature Biotechnology (2011)
-
Pharmacy and pharmacology of biosimilars
Journal of Endocrinological Investigation (2008)
-
Generika in Österreich 2003–2008: ein Update
Wiener klinische Wochenschrift (2008)
-
Biosimilars: the impact of their heterogeneity on regulatory approval
Nature Reviews Drug Discovery (2007)